Scholarlink

Background <p>While neoadjuvant immunochemotherapy has improved outcomes of resectable nonsmall cell lung cancer (NSCLC), treatment-induced tissue changes can increase surgical complexity. This study aimed to identify preoperative predictors of technically challenging surgery following neoadjuvant immunochemotherapy.</p> Patients and Methods <p>This multicenter retrospective analysis included 114 patients who underwent surgery after neoadjuvant nivolumab plus platinum-based chemotherapy at 29 institutions between March 2023 and July 2024. Challenging surgery was defined as one requiring bronchoplasty, pulmonary artery angioplasty, or pneumonectomy. Logistic regression was used to identify preoperative predictors for surgical complexity.</p> Results <p>Twenty-one patients (18.4%) required challenging surgeries, including bronchoplasty (<i>n</i> = 13), pulmonary artery angioplasty (<i>n</i> = 1), double-sleeve resection (<i>n</i> = 4), and pneumonectomy (<i>n</i> = 3). These cases had longer operative times (340 ± 118 vs. 267 ± 98 min, <i>p</i> &lt; 0.001) and more frequently required open thoracotomy (90.5% vs. 44.1%, <i>p</i> &lt; 0.001). Conventional predictive factors (T/N status, programmed cell death ligand expression, radiological response, and treatment-to-surgery interval) showed no association with surgical complexity. Post-treatment extranodal extension (ENE) after neoadjuvant therapy and before surgery was the strongest predictor of challenging surgery (univariable odds ratio [OR] 7.06, 95% confidence interval [CI]: 1.45–34.41, <i>p</i> = 0.009). Post-treatment ENE demonstrated a higher predictive accuracy for challenging surgery (positive predictive value [PPV] 50.0%) than that of pathological ENE metastasis (PPV 14.3%); thus, positivity reflects treatment-induced anatomical changes rather than residual tumor invasion.</p> Conclusions <p>Unlike conventional predictors, post-treatment ENE may predict surgical complexity after neoadjuvant immunochemotherapy. ENE may be a potential marker of treatment-induced anatomical complexity rather than residual tumor burden, enabling evidence-based surgical planning in the immunotherapy era.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer

  • 期刊论文

  • 发表日期：

    2026年6月17日

查看全文
  • Shinya Tane,
  • Kotaro Nomura,
  • Takuya Watanabe,
  • Shinkichi Takamori,
  • Shuta Ohara,
  • Hana Oiki,
  • Shinya Katsumata,
  • Satoshi Takamori,
  • Marina Nakatsuka,
  • Hironori Tenpaku,
  • Ryuji Nakamura,
  • Hirotsugu Notsuda,
  • Kei Namba,
  • Kentaro Minegishi,
  • Yoshitaka Kitamura,
  • Miyuki Abe,
  • Kyoshiro Takegahara,
  • Hayato Konno,
  • Kiyomichi Mizuno,
  • Takahide Toyoda,
  • Satoshi Muto,
  • Michihito Toda,
  • Makoto Endo,
  • Yoshimasa Maniwa,
  • Junichi Soh,
  • Yasuhisa Ohde

摘要

Background

While neoadjuvant immunochemotherapy has improved outcomes of resectable nonsmall cell lung cancer (NSCLC), treatment-induced tissue changes can increase surgical complexity. This study aimed to identify preoperative predictors of technically challenging surgery following neoadjuvant immunochemotherapy.

Patients and Methods

This multicenter retrospective analysis included 114 patients who underwent surgery after neoadjuvant nivolumab plus platinum-based chemotherapy at 29 institutions between March 2023 and July 2024. Challenging surgery was defined as one requiring bronchoplasty, pulmonary artery angioplasty, or pneumonectomy. Logistic regression was used to identify preoperative predictors for surgical complexity.

Results

Twenty-one patients (18.4%) required challenging surgeries, including bronchoplasty (n = 13), pulmonary artery angioplasty (n = 1), double-sleeve resection (n = 4), and pneumonectomy (n = 3). These cases had longer operative times (340 ± 118 vs. 267 ± 98 min, p < 0.001) and more frequently required open thoracotomy (90.5% vs. 44.1%, p < 0.001). Conventional predictive factors (T/N status, programmed cell death ligand expression, radiological response, and treatment-to-surgery interval) showed no association with surgical complexity. Post-treatment extranodal extension (ENE) after neoadjuvant therapy and before surgery was the strongest predictor of challenging surgery (univariable odds ratio [OR] 7.06, 95% confidence interval [CI]: 1.45–34.41, p = 0.009). Post-treatment ENE demonstrated a higher predictive accuracy for challenging surgery (positive predictive value [PPV] 50.0%) than that of pathological ENE metastasis (PPV 14.3%); thus, positivity reflects treatment-induced anatomical changes rather than residual tumor invasion.

Conclusions

Unlike conventional predictors, post-treatment ENE may predict surgical complexity after neoadjuvant immunochemotherapy. ENE may be a potential marker of treatment-induced anatomical complexity rather than residual tumor burden, enabling evidence-based surgical planning in the immunotherapy era.